

**Final Agenda**  
**39<sup>th</sup> meeting of the Committee for Risk Assessment**

**28 November – 9 December 2016**

**ECHA Conference Centre (Annankatu 18, Helsinki)**

**28 November starts at 14.00**  
**2 December breaks at 13.00**  
**7 December resumes at 9.00**  
**9 December ends at 13.00**

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***RAC/A/39/2016***  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

***For information***

**Item 4 – Report from other ECHA bodies and activities**

- a) Report on RAC 38 action points, written procedures and update on other ECHA bodies

***RAC/39/2016/01***

***RAC/39/2016/02***

***Room document***

***For information***

- b) RAC workplan for all processes

***For information***

**Item 5 – Requests under Article 77 (3)(c)**

No requests.

## Item 6 – Requests under Article 95 (3)

- a) 1-methyl-2-pyrrolidone (NMP)

**RAC/39/2016/03**  
**Restricted room document**  
**For discussion**

- b) OEL-DNEL methodology request

**RAC/39/2016/04**  
**Restricted document**  
**For discussion**

## Item 7 – Harmonised classification and labelling (CLH)

### 7.1 General CLH issues

### 7.2 CLH dossiers

#### A. Hazard classes for agreement without plenary debate (fast-track)

- Asulam sodium: physical hazards, acute toxicity, serious eye damage / eye irritation, STOT SE, STOT RE, respiratory sensitisation, germ cell mutagenicity, carcinogenicity, toxicity to reproduction, environmental hazards
- XTJ568: acute toxicity, skin corrosion (incl. additional labelling with EUH071), serious eye damage, germ cell mutagenicity
- Thifensulfuron-methyl (ISO): environmental hazards
- Propiconazole (ISO): acute toxicity (oral route of exposure), skin sensitisation, environmental hazards
- Mesosulfuron-methyl: physical hazards, acute toxicity, serious eye damage / eye irritation, STOT SE, STOT RE, respiratory or skin sensitisation, germ cell mutagenicity, carcinogenicity, toxicity to reproduction, aspiration hazard

#### B. Hazard classes for agreement with plenary debate

- a) 1-vinylimidazole
- b) Colecalciferol, vitamin D3
- c) Asulam sodium
- d) Potassium permanganate
- e) XTJ568; reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-([2-(2-aminobutoxy)ethoxy]methyl)propoxy)but-2-ylamine
- f) Tris(2-ethylhexyl) 4,4',4''-(1,3,5-triazine-2,4,6-triyltriimino)tribenzoate
- g) Thifensulfuron-methyl (ISO); methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate
- h) Propane-1,2-diol
- i) Propiconazole (ISO)

- j) Mesosulfuron-methyl; methyl 2-[[[4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl]-4-[[[(methylsulfonyl)amino]methyl]benzoate
- k) Spirodiclofen (ISO)

***For discussion and adoption***

### **C. Presentation of key issues**

- a) Glyphosate (ISO)

***For discussion***

### **7.3 Appointment of RAC (co-)rapporteurs for CLH dossiers**

***RAC/39/2016/05***

***Restricted room document***

***For agreement***

## **Item 8 – Restrictions**

### **8.1 Restriction Annex XV dossiers**

- a) Conformity check
  - 1. Diisocyanates – outcome of conformity check and presentation of key issues

***For agreement***

- b) Opinion development

- 1. TDFAs – second draft opinion
- 2. 4 phthalates- second draft opinion

***For discussion/agreement***

### **8.2 Appointment of (co-)rapporteurs for restriction dossiers**

***For information***

## **Item 9 – Authorisation**

### **9.1 General authorisation issues**

- a) Update on incoming/future applications
- b) Report on AfA Task Force and related activities

***For information***

## 9.2 Authorisation applications

### a) Outcome of the conformity check and presentation of the key issues

1. CT\_Hapoc\_2 (1 use)
2. CT\_Hapoc\_3 (1 use)
3. CT\_Haas (1 use)
4. SD\_Haas (1 use)
5. PD\_Haas (1 use)
6. CT\_Reachlaw (4 uses)
7. CT\_Clariant (1 use)
8. CT\_ZFL (2 uses)
9. SD\_ZFL (1 use)
10. CT\_Cryospace (1 use)
11. SC\_AviAll (2 uses)
12. SD\_Borealis (1 use)
13. SD\_Ormezzano (2 uses)
14. AD\_BAE (2 uses)
15. EDC\_Biotech (1 use)
16. EDC\_ORGAPHARM (2 uses)
17. EDC\_Akzo (1 use)
18. EDC\_Bayer (1 use)
19. EDC\_Olon (2 uses)
20. MOCA\_Reachlaw (1 use)

***For agreement***

### b) Agreement on Draft Opinions

1. Diglyme\_Merck (1 use)
2. Diglyme\_Isochem (1 use)
3. Diglyme\_Roche (1 use)
4. Diglyme\_LifeTech (1 use)
5. Diglyme\_Acton (2 uses)
6. Diglyme\_Bracco (1 use)
7. Diglyme\_Maflon (1 use)
8. Chromium trioxide\_HAPOC (4 uses) (CT\_HAPOC)
9. Potassium dichromate GENTROCHEMA BV (2 uses) (PD\_Gentrochema)
10. Sodium dichromate GENTROCHEMA BV (3 uses) (SD\_Gentrochema)
11. Technical MDA\_Polynt (2 uses)
12. EDC\_Eurenco (1 use)

***For discussion and/or agreement***

### c) Adoption of final opinions

1. Chromium trioxide\_Cromomed (1 use) (CT\_Cromomed)
2. Chromium trioxide\_Burscheid (1 use) (CT\_Burscheid)
3. Chromium trioxide\_Friedberg (1 use) (CT\_Friedberg)
4. Chromium trioxide\_Valvetrain (1 use) (CT\_Valvetrain)

5. Sodium dichromate\_Akzo (2 uses) (SD\_Akzo)
6. Sodium dichromate\_Arkema (1 use) (SD\_Arkema)
7. Chromic acid\_Bosch (1 use) (CA\_Bosch)
8. Potassium dichromate\_Brenntag (2 uses) (PD\_Brenntag)
9. Sodium dichromate\_Brenntag (3 uses) (SD\_Brenntag)
10. Dichromium tris(chromate)\_Henkel (2 uses) (DtC\_Henkel)
11. Strontium chromate\_Akzo (2 uses) (ST\_Akzo)
12. Potassium hydroxyoctaoxodizincatedichromate\_PPG (2 uses) (PH\_PPG)

***For discussion and adoption***

### **9.3 Appointment of (co-)rapporteurs for authorisation applications**

***RAC/39/2016/06***

***Restricted room document***

***For agreement***

**Item 10 – AOB**

**Item 11 – Action points and main conclusions of RAC-39**

Table with Conclusions and Action points from RAC-39

***For adoption***